REFERENCES
- Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74–108.
- Belani CP, Langer C, TAX 326 Study Group. First-line chemotherapy for NSCLC: an overview of relevant trials. Lung Cancer 2002;38(Suppl 4):13–19.
- Gridelli C, Rossi A, Maione P. Treatment of non-small cell lung cancer: state of the art and development of new biological agents. Oncogene 2003;22:6629–6638.
- Kumar S, Guleria R, Singh V, Bharti AC, Mohan A, Das BC. Efficacy of plasma vascular endothelial growth factor in monitoring first-line chemotherapy in patients with advanced non-small cell lung cancer. BMC Cancer 2009, 9, 421.
- Kumar S, Guleria R, Singh V, Bharti AC, Mohan A, Das BC. Plasma nucleosome levels might predict response to therapy in patients with advanced non-small cell lung cancer. Clin Lung Cancer 2010;11:36–44.
- Endo S, Sato Y, Hasegawa T, Tetsuka K, Otani S, Saito N, Tezuka Y, Sohara Y. Preoperative chemotherapy increases cytokine production after lung cancer surgery. Eur J Cardiothorac Surg 2004;26:787–791.
- Kong FM, Washington MK, Jirtle RL, Anscher MS. Plasma transforming growth factor β1 reflects disease status in patients with lung cancer after radiotherapy: a possible tumor marker. Lung Cancer 1996;16:47–59.
- Kong FM, Jirtle RL, Huang DH, Clough RW, Anscher MS. Plasma transforming growth factor-β1 level before radiotherapy correlates with long-term outcome of patients with lung carcinoma. Cancer 1999;86:1712–1719.
- Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor β in human disease. N Engl J Med 2000;342: 1350–1358.
- Wakefield ML, Roberts AB. The two faces of transforming growth factor β in carcinogenesis. Proc Natl Acad Sci USA 2003;100: 8621–8623.
- Jakowlew SB. Transforming growth factor-β in cancer and metastasis. Cancer Metastasis Rev 2006;25:435–457.
- Kong FM, Anscher MS, Murase T, Abbott BD, Iglehart JD, Jirtle RL. Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg 1995;222:155–162.
- Mountain CF. Revision in the international system for staging lung cancer. Chest 1997;111:1710–1717.
- Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results in cancer treatment. Cancer 1981;47:207–214.
- Yang EY, Moses HL. Transforming growth factor β1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J Cell Biol 1990;111:731–741.
- Ueki N, Nakazato M, Ohkawa T, Ikeda T, Amuro Y, Hada T, Higashino K. Excessive production of transforming growth factor-β1 can play an important role in the development of tumorigenesis by its action for angiogenesis: validity of neutralizing antibodies to block tumor growth. Biochim Biophys Acta 1992;1137:189–196.
- Massague J. The transforming growth factor-β family. Annu Rev Cell Biol 1990;6:597–641.
- Hsu S, Huang F, Hafez M, Winawer S, Friedman E. Colon carcinoma cells switch their response to transforming growth factor-β1 with tumor progression. Cell Growth Diff 1994;5:267–275.
- Söderdahl G, Betsholtz C, Johansson A, Nilsson K, Bergh J. Differential expression of platelet-derived growth factor and transforming growth factor genes in small and non-small cell human lung carcinoma lines. Int J Cancer 1988;41:636–641.
- Jakowlew SB, Mathias A, Chung P, Moody TW. Expression of transforming growth factor β ligand and receptor messenger RNAs in lung cancer cell lines. Cell Growth Diff 1995;6:465–476.
- Nørgaard P, Spang-Thomsen M, Poulsen HS. Expression and autoregulation of transforming growth factor beta receptor mRNA in small-cell lung cancer cell lines. Br J Cancer 1996;73:1037–1043.
- Kumar S, Guleria R, Singh V, Mohan A, Bharti AC, Das BC. Lack of utility of plasma TNF-alpha level in predicting therapeutic efficacy in patients with advanced non-small cell lung cancer. Cytokine 2010;51:245–248.